CAJ | 학술논문

目的探讨冠心病患者血浆脂联素水平与冠状动脉粥样硬化病变的关系.方法根据选择性冠状动脉造影结果将142例患者分为冠心痛组和对照组.冠心病组根据临床诊断分为稳定型心绞痛(SAP)组和急性冠脉综合征(ACS)组;根据冠状动脉病变类型分为A型病变、B型病变和C型病变组;根据冠状动脉病变程度分为轻度病变、中度病变和重度病变组.血浆脂联素浓度通过ELISA方法测定.结果冠心病组脂联素浓度明显低于对照组((6.09±1.85)μg/ml vs(10.25±1.51)μg/ml,P＜0.001),ACS组脂联素浓度又明显低于SAP组(5.45±1.53)μg/ml vs(7.60±1.67)μg/ml,P＜0.001).随冠状动脉病变类型和病变程度的加重,脂联素浓度逐渐降低,各组间差异有统计学意义(P＜0.001).结论脂联素是冠状动脉粥样硬化的负调控因子,低脂联素血症可以做为预测冠状动脉粥样硬化病变情况及斑块稳定性的一个指标.
목적 탐토관심병환자혈장지련소수평여관상동맥죽양경화병변적관계.방법 근거선택성관상동맥조영결과장142례환자분위관심통조화대조조.관심병조근거림상진단분위은정형심교통(SAP)조화급성관맥종합정(ACS)조;근거관상동맥병변류형분위A형병변、B형병변화C형병변조;근거관상동맥병변정도분위경도병변、중도병변화중도병변조.혈장지련소농도통과ELISA방법측정.결과 관심병조지련소농도명현저우대조조((6.09±1.85)μg/ml vs(10.25±1.51)μg/ml,P＜0.001),ACS조지련소농도우명현저우SAP조(5.45±1.53)μg/ml vs(7.60±1.67)μg/ml,P＜0.001).수관상동맥병변류형화병변정도적가중,지련소농도축점강저,각조간차이유통계학의의(P＜0.001).결론 지련소시관상동맥죽양경화적부조공인자,저지련소혈증가이주위예측관상동맥죽양경화병변정황급반괴은정성적일개지표.
Objective To investigate the relationship between the plasma adiponectin concentration and coronary arteriosclerosis change in patient with coronary heart disease(CHD).Method 142 patients were divided into CHD group and control group according to the Coronary Angiography(CAG).CHD group were further divided into stable angina pectoris(SAP)subgroup and acute coronary syndrome (ACS)subgroup according to the clinical property.According to the type of coronary change,CHD group wag divided into A type group, B type group and C type group,meanwhile according to the degree of coronary lesion,CHD group was divided into light stenosis group, moderate stenosis group and severe stenosis group.The plasma adiponectin concentration was measured by ELISA.Results The plasma adiponectin concentration in CHD group was significant lower than that in control group.The plasma adiponectin concentration in ACS subgroup was significant lower than that in SAP subgroup.The plasma adiponectin concentration decreased gradually from A type group to C type group and from light stenosis group to severe stenosis group(P＜0.001).Conclusions Adiponectin is a negative regulatory factor of coronary atherosclerosis,and Hypoadiponectin may be used to predict the change of coronary arteriosclerosis and the stability of plaque.